Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

This study is testing a focused ultrasound technique that temporarily opens the blood-brain barrier — the protective shield around the brain — to help deliver doxorubicin (a chemotherapy drug) more effectively into brain tumors. It is designed for children and young adults with DIPG (diffuse intrinsic pontine glioma), an extremely aggressive brainstem tumor. **You may be eligible if...** - You are between 5 and 21 years old (younger children may be considered case-by-case) - You have been diagnosed with DIPG - It has been at least 4 weeks but no more than 12 weeks since you completed radiation therapy - You are neurologically stable for at least 7 days - If you are on steroids, the dose has been stable or decreasing for at least 7 days - You have a life expectancy of at least 6 months **You may NOT be eligible if...** - Your tumor is not visible on imaging - You previously received chemotherapy or targeted therapy in a clinical trial - You have signs of increased brain pressure - You have a ventricular-peritoneal shunt, cerebral aneurysm, or vascular malformation - You are taking blood thinners or medications that increase bleeding risk - You have HIV or active seizures - You have a known allergy to the ultrasound contrast agent or doxorubicin Talk to your doctor to see if this trial is right for you.